- The disease
- Flexible endoscopes are used in diagnostic and therapeutic procedures such as colonoscopies and bronchoscopies. Because they cannot be heat-sterilised, they require careful chemical reprocessing between uses to prevent transmission of pathogens between patients. Inadequate reprocessing has been linked to healthcare-associated infection outbreaks in multiple countries. Regulatory bodies including the US Food and Drug Administration (FDA) have issued guidance on endoscope reprocessing standards.
- What the asset is trying to do
- CORIS is a medical device product developed by Nanosonics (ASX: NAN) for endoscope reprocessing. No mechanism detail or technical specification for CORIS has been disclosed in the input data provided. the specific reprocessing technology (for example, chemical, ultrasonic, or other modality) and how it differs from existing automated endoscope reprocessors currently on the market.
- What the trial is measuring, and why it matters
- The trial endpoints for CORIS have not been disclosed in the input data provided. the primary and secondary endpoints, which for an endoscope reprocessing device study would typically relate to measures such as microbiological efficacy, device residue, or user workflow metrics. The significance of those endpoints depends on the regulatory pathway and intended labelling claims.
- Efficacy benchmarks in this setting
- Existing automated endoscope reprocessors on the market -- such as those cleared or approved by the FDA and equivalent bodies -- have established benchmarks for high-level disinfection (HLD) efficacy under standards including ANSI/AAMI ST91 and relevant FDA guidance documents. Specific disinfection efficacy figures for cleared devices are described in their respective 510(k) summaries or product labelling available via the FDA device database. Because CORIS is at an early evaluation stage, any performance figures generated to date are not statistically comparable to the body of evidence supporting cleared devices.
- Commercial context
- Nanosonics is an ASX-listed company whose existing commercial product, trophon, is an automated ultrasound probe disinfection device sold in multiple markets. CORIS represents a separate pipeline asset targeting the endoscope reprocessing market. No regulatory clearance or approval for CORIS has been disclosed. No partnership, licensing, or manufacturing deal for CORIS has been publicly announced. whether CORIS is designated as Nanosonics' lead pipeline asset and any further commercial context from company filings.